


## INDEX TO VOLUME 4

## AUTHOR INDEX

ATRIA, P., 155  
 AZNAR-RAMOS, R., 37  
 BEHRMAN, H.R., 229  
 BHASIN, K., 375  
 BORIA, M.C., 193  
 BORIS, A., 97  
 BROEN, E.M., 313  
 BUCH, N.C., 105  
 BYGDEMAN, M., 293  
 CHANDRA, H., 253  
 CHEVIAKOFF, S., 155  
 CHOWDHURY, S.R., 253  
 CLEMETSON, C.A.B., 183  
 CROXATTO, H.B., 155  
 DALE, E., 241  
 DASGUPTA, P.R., 253  
 DECHERNEY, A., 267  
 DIAZ, S., 155  
 DORFMAN, R.I., 15  
 DROBNY, H., 267  
 EGG, D., 91  
 FORBES, A.D., 31  
 GALLEGOS, A.J., 169  
 GINER-VELAZQUEZ, J., 37  
 GORDON, M., 193  
 GREEP, R.O., 229  
 GUPTA, P.K., 375  
 HEINEN, G., 393  
 HOAG, E.J., 327  
 HOPKINS, J.C., 365  
 HOPKINS, T.F., 365  
 HORNE, H.W., Jr., 337  
 HOROWITZ, A.J., 23  
 INGEMANSON, C-A., 305  
 JANAKIRAMAN, K., 105  
 JOCHLE, W., 1  
 JOSHI, S.G., 45  
 KALESH, D.G., 183  
 KAMBOJ, V.P., 253  
 KAR, A.B., 253  
 KOSASA, T., 253  
 KIRTON, K.T., 31  
 KUTNER, S.J., 327  
 LEDOUX-CORBUSIER, M., 79  
 LOEWIT, K., 91  
 MALKANI, P.K., 375  
 MALLIKARJUNESWARA, V.R., 183  
 MARTINEZ-MANAUTOU, J., 37  
 MELTON, R.J., 319  
 MORRIS, J.M., 15  
 MUELLER, H., 223  
 NELSON, E.W., Jr., 97  
 NICKERSON, L.M., 365  
 ODDO, H., 155  
 OSTREGARD, D.R., 313  
 PHILLIPS, N.R., 327  
 PRENEN, M., 79  
 RAGAB, M.I., 199  
 REITER, R.J., 385  
 ROSATTI, S., 155  
 SCHROGIE, J.J., 223, 401  
 SCIARRA, J.J., 23  
 SCHUMACHER, G.F.B., 67  
 SETTY, B.S., 253  
 SHELTON, J.D., 319  
 SHULMAN, S., 135  
 SORRENTINO, S., Jr., 385  
 SPIVEY, S.H., 241  
 SPRAGUE, J., 267  
 STONE, M.L., 193  
 TOPPOZADA, M., 293  
 TRMAL, T., 97  
 VAN WAGENEN, G., 15  
 VEERHUSEN, P.G., 23  
 WIQVIST, N., 293  
 ZALDIVAR, A., 169  
 ZAMBELIS, N., 91



## INDEX TO VOLUME 4

### SUBJECT INDEX

Abortifacient efficacy, prostaglandin F<sub>2α</sub> (monkey), 31  
Abortion  
    aminoglutethimide potentiation of estrogen-induced (rat), 229  
    intra-amniotic administration of prostaglandin F<sub>2α</sub>, 293  
    jet ejector vacuum cannula, 199  
17α-Acetoxy-6-methyl-pregna-4,6-diene-3,20-dione (megestrol acetate)  
Acne, hormonal contraceptives, 79  
Alpha<sub>1</sub>-antitrypsin, inhibition of sperm acrosomal protease (rabbit), 67  
Alpha<sub>1x</sub>-antichymotrypsin, inhibition of sperm acrosomal protease (rabbit), 67  
Aminoglutethimide potentiation of estrogen-induced abortion (rat), 229  
Antifertility activity, dl-cis-bisdehydrodoisynolic acid methyl ether (rabbit and monkey), 15  
Anti-ovulatory compounds, pubertal ovulation for study of (rat), 97  
Ascorbic acid concentration, effect by estrogen-containing oral contraceptives, 183  
Bioassays and radioimmunoassay in assessing GEF activity, 365  
Biology and pathology of reproduction, Greek mythology, 1  
Cellular response to IUD in uterine cavity, 375  
dl-cis-Bisdehydrodoisynolic acid methyl ether, 15  
Chloasma, hormonal contraceptives, 79  
Chlormadinone acetate, 37  
    contraceptive efficacy, single and divided doses, 37  
Combination and sequential oral contraceptives, discriminating use, 393  
Combination oral contraceptive, serum proteins, 241  
Continuation rates, oral contraceptives and Dalkon Shield, 319  
Contraceptive action of megestrol acetate implants, 155  
Contraceptive effect, iron (rat), 91  
Contraceptive efficacy, chlormadinone acetate, 37  
Contraceptive methods, Greek mythology, 1  
Dalkon Shield, 313 & 319  
Depression, oral contraceptives, 327  
Dermatology, hormonal contraceptives, 79  
Discriminating use of combination and sequential oral contraceptives, 393  
Divided dose, chlormadinone acetate, 37  
Essential dietary nutrients and oral contraceptives, workshop, 223  
Estradiol dipropionate (monkey), 253  
    response by ovariectomized genital organs, 253  
Estrogen-containing oral contraceptives, effect on ascorbic acid concentration, 183

## CONTRACEPTION

Estrogen-induced abortion, aminoglutethimide potentiation (rat), 229  
13 $\beta$ -Ethyl-17 $\alpha$ -ethynodiol-hydroxygome-4-ene-3-one (Norgestrel)  
Ethynodiol diacetate-mestranol  
    combination oral contraceptive, 241  
    serum proteins, 241  
Fertility regulating agencies in U.S., 401  
GEF (gonadotropin-enhancing factors), 365  
Genital organs, ovariectomized, response to sex hormones (monkey), 253  
Gestation, effect of propylthiouracil on hormone levels, 337  
Gonadotropin-enhancing factors (GEF), 365  
Greek mythology, biology and pathology of reproduction, 1  
Hormonal contraceptives and dermatology, 79  
Hormone levels of early gestation, effect of propylthiouracil, 337  
Idiopathic hirsutism, hormonal contraceptives, 79  
Immunity and infertility, review, 135  
Immunologic aspermatogenesis and orchitis, 135  
Implants, megestrol acetate, 155  
Infertility and immunity, review, 135  
Injectable progestational contraceptive, serum proteins, 241  
Interaction between oral contraceptives and essential dietary nutrients, workshop, 223  
Inter-alpha-trypsin inhibitor, inhibition of sperm acrosomal protease (rabbit), 67  
Intra-amniotic administration  
    prostaglandin F<sub>2a</sub>, 293  
    prostaglandin F<sub>2a</sub> (monkey), 31  
Iron, contraceptive effect (rat), 91  
Iron chloride, contraceptive effect (rat), 91  
IUD (see also IUFB), 105, 267, 305, 313 & 375  
    cellular response in uterine cavity, 375  
    Dalkon Shield, 313  
    Lippes Silicone-Shell loop, 305  
    " M " intrauterine contraceptive device, 193  
    Majzlin spring, 23  
    private practitioner acceptance, 267  
    structural changes after insertion, 375  
IUD related to other contraceptives, private practitioner acceptance, 267  
IUD versus pill, continuation rates, 319  
IUD-mediated effect on uterine histology (water buffalo), 105  
IUFB (see also IUD), 45  
    macrophage accumulation in uterine cavity (baboon), 45  
Jet ejector vacuum cannula for abortion, 199  
Lippes Silicone-Shell loop, 305  
Luteinizing hormone and ovulation, inhibition by melatonin (rat), 385  
" M " intrauterine contraceptive device, 193

## CONTRACEPTION

Macrophage accumulation in uterine cavity with IUBF (baboon), 45  
Majzlin spring, 23  
    contraceptive effectiveness, 23  
    side effects, 23  
Medroxyprogesterone acetate ( $\delta$ - $\alpha$ -methyl-17-acetoxy-pregn-4-ene-3,20-dione), 241  
    long-acting injectable contraceptive, 241  
    serum proteins, 241  
Megestrol acetate ( $17\alpha$ -acetoxy- $\delta$ -methyl-pregna-4,6-diene-3,20-dione), 155  
    contraceptive action of implants, 155  
Melatonin, effect on luteinizing hormone and ovulation (rat), 385  
Metabolism, d-Norgestrel, 169  
Methallibure ( $1-\alpha$ -methylallylthiocarbamoyl-2-methylthiocarbamoylhydrazine), 97  
 $\delta$ - $\alpha$ -Methyl-17-acetoxy-pregn-4-ene-3,20-dione (medroxyprogesterone acetate)  
 $1-\alpha$ -Methylallylthiocarbamoyl-2-methylthiocarbamoylhydrazine (methallibure)  
Minnesota Multiphasic Personality Inventory (MMPI), 327  
Norgestrel ( $13\beta$ -ethyl- $17\alpha$ -ethynyl- $17\beta$ -hydroxygone-4-ene-3-one), 169  
d-Norgestrel, 169  
    metabolism, 169  
    tissue localization, 169  
Oral contraceptives, personality and changes in depression, 327  
Oral contraceptives and essential dietary nutrients, workshop, 223  
Ovariectomized, genital organ response to sex hormones (monkey), 253  
Ovulation and luteinizing hormone, inhibition by melatonin (rat), 385  
Pathology of reproduction, Greek mythology, 1  
Personality and changes in depression, oral contraceptives, 327  
Pill versus IUD, continuation rates, 319  
Pilosebaceous complications, hormonal contraceptives, 79  
Plasma ascorbic acid, effect by estrogen-containing oral contraceptives, 183  
Platelet ascorbic acid, effect by estrogen-containing oral contraceptives, 183  
Porphyria cutanea tarda, hormonal contraceptives, 79  
Postcoital administration, dl-cis-Bisdehydrodoisynolic acid methyl ether (rabbit and monkey), 15  
Pregnant mare's serum (PMS) treated immature rats, 385  
Private practitioner acceptance of IUD, 267  
Progesterone (monkey), 253  
    response by ovariectomized genital organs, 253  
Propylthiouracil, effect on hormone levels of early gestation, 337  
Prostaglandin F<sub>2a</sub>, 31 & 293  
    abortifacient efficacy (monkey), 31  
    intra-amniotic administration, 293  
Pubertal ovulation for study of anti-ovulatory compounds (rat), 97  
Radioimmunoassay and bioassays in assessing GEF activity, 365  
Reduction of fertility by immunization, 135  
Resistant seborrheic alopecia, hormonal contraceptives, 79

## CONTRACEPTION

Sequential and combination oral contraceptives, discriminating use, 393  
Serum proteins  
    combination oral contraceptive, 241  
    injectable progestational contraceptive, 241  
Side effects, Majzlin spring, 23  
Silastic capsules, megestrol acetate, 155  
Silicone-Shell loop, Lippes, 305  
Single dose, chlormadinone acetate, 37  
Sperm acrosomal protease, inhibition (rabbit), 67  
Sperm antibodies in humans, 135  
Structural changes in IUD after insertion, 375  
Tissue localization, d-Norgestrel, 169  
Trypsin Kallikrein inhibitor, inhibition of sperm acrosomal protease (rabbit), 67  
Uterine cavity  
    cellular response to IUD, 375  
    macrophage accumulation with IUFB (baboon), 45  
Uterine histology, interference by IUD (water buffalo), 105  
Vaginal application of iron chloride, contraceptive effect (rat), 91  
Vulvo-vaginitis, hormonal contraceptives, 79

N



1